NanoCarrier Co., Ltd. (JP:4571)

:4571

4571

NanoCarrier Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4571 full AI Analyst Report?

NanoCarrier Co., Ltd. (4571) Price & Analysis

2 Followers

4571 Stock Chart & Stats

¥134.00

-¥1.00(-0.68%)

At close: Jan 08 4:00 PM EST

¥134.00

-¥1.00(-0.68%)

Day’s Range― - ―

52-Week Range¥124.00 - ¥254.00

Previous CloseN/A

Volume236.30K

Average Volume (3M)2.35M

Market Cap

¥11.09B

Enterprise Value¥8.34B

Total Cash (Recent Filing)¥3.40B

Total Debt (Recent Filing)¥540.24M

Price to Earnings (P/E)―

Beta0.91

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding82,786,760

10 Day Avg. Volume484,410

30 Day Avg. Volume2,345,523

Financial Highlights & Ratios

PEG Ratio-1.80

Price to Book (P/B)3.71

Price to Sales (P/S)93.58

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary DDS Micellar Nanoparticle PlatformNanoCarrier's proprietary micellar DDS platform is a durable technological asset that supports licensing, milestone and royalty revenue models. A platform focus in oncology increases partner interest and creates repeatable collaboration opportunities that can generate sustained non-dilutive cash flows.

High Gross Margins (~72% In FY2025)Sustained high gross margins indicate strong unit economics for the company's core technology and services. If revenue stabilizes or grows via partnerships, these margins support positive contribution to profits, enabling more efficient R&D funding per revenue dollar over the medium term.

Manageable Leverage; Debt Materially ReducedLow debt-to-equity and materially reduced total debt provide financial flexibility and lower interest burden, improving the company's capacity to absorb operating losses, negotiate deals, and pursue development partnerships without immediate refinancing pressure.

Bears Say

Persistent Cash Burn; Negative Operating Cash FlowConsistent negative operating cash flow demonstrates the business cannot self-fund operations and must rely on financing, partners or asset monetization. Over time this increases dilution or refinancing risk and constrains strategic flexibility if partner payments do not materialize.

Shrinking Revenue TrendA multi-year revenue decline erodes scale and undermines operating leverage, making it harder to absorb fixed R&D and SG&A costs. Structural revenue weakness reduces partner bargaining power and delays the path to sustainable profitability absent new collaborations or product progress.

Very Large Operating And Net LossesExtremely negative net margins and large operating losses continually erode equity and returns. This structural unprofitability limits reinvestment capacity, raises solvency concerns over time, and makes the business highly reliant on external funding or milestone receipts to survive.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

3M ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

8M ago

4571 FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was ¥124.00 and its highest was ¥254.00 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is ¥11.09B.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

Currently, no data Available

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 82,786,760 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4571

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.